In a market leaning toward the overvalued side, investors must dig deeper to unearth buying opportunities.
We think stockpicking--rather than macro guessing--is the way to excess returns.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.
Blockbuster sales and takeover potential create an attractive risk/reward tradeoff for this speculative biotech.
The contract research organization industry's recovery is finally making its way into earnings and valuations.
Parexel's Jim Winschel speaks to Morningstar's Lauren Migliore.
The current stock price assigns almost no value to this top-tier CRO's preclinical services segment.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
Contract research organizations remain on sale as industry rebound gains steam.
Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Parexel CFO Jim Winschel on the benefits of contract versus in-house research for pharma firms, the advantages of global operations, and recent business acceleration.
We see opportunity as fleeing investors trigger an irrational sell-off.
Market uncertainty has uncovered opportunity in this high-growth sector.
Despite bookings improvement, firms continue to trade below fair value.
These highly anticipated new therapies are about to face judgment day.
Near-term demand remains choppy, but bookings growth shows CRO model promise.
Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.
Gen-Probe's CFO Herm Rosenman says the firm has plenty of catalysts that should drive growth for the next several years.
As megamergers wind down, biotechs continue to represent attractive targets for big pharma.
Slow growth persists among CROs, but we see a rebound on the horizon.
The near-term environment remains tough, but we're bullish on the CROs' long-term prospects.
Morningstar has a new approach to rating the riskiest of biotechs.